Search Results for "R"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for R. Results 491 to 500 of 999 total matches.

Sirolimus (Rapamune) for Transplant Rejection

   
The Medical Letter on Drugs and Therapeutics • Feb 07, 2000  (Issue 1071)
. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Richard Kim, M.D., Vanderbilt ...
Sirolimus, whlch is structurally related to tacrolimus, has been approved by the FDA for prevention of acute renal transplant rejection. The manufacturer recommends that sirolimus be taken with cyclosporine and corticosteroids.
Med Lett Drugs Ther. 2000 Feb 7;42(1071):13-4 |  Show IntroductionHide Introduction

Bexarotene (Targretin) For Cutaneous T-cell Lymphoma

   
The Medical Letter on Drugs and Therapeutics • Apr 03, 2000  (Issue 1075)
Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D ...
Bexarotene, a retinoid analog, has been approved by the US Food and Drug Administration for oral treatment of dermatologic manifestations of refractory cutaneous T-cell lymphoma.
Med Lett Drugs Ther. 2000 Apr 3;42(1075):31-2 |  Show IntroductionHide Introduction

Colesevelam (Welchol) For Hypercholesterolemia

   
The Medical Letter on Drugs and Therapeutics • Oct 30, 2000  (Issue 1091)
., University Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D ...
Colesevelam hydrochloride (Welchol - Sankyo Pharma), a nonabsorbed hydrophilic polymer that binds bile acids, has been approved by the FDA for reduction of plasma LDL cholesterol in patients with primary hypercholesterolemia.
Med Lett Drugs Ther. 2000 Oct 30;42(1091):102-4 |  Show IntroductionHide Introduction

Drugs For Vulvovaginal Candidiasis

   
The Medical Letter on Drugs and Therapeutics • Jan 08, 2001  (Issue 1095)
, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University ...
Many drugs, mostly azole derivatives, are marketed in the USA for topical treatment of vulvovaginal candidiasis. A single-dose, sustained-release formulation of butoconazole nitrate 2% cream (Gynazole 1) is the newest addition. Fluconazole (Diflucan) is approved for single-dose oral treatment.
Med Lett Drugs Ther. 2001 Jan 8;43(1095):3-4 |  Show IntroductionHide Introduction

Synagis Revisited

   
The Medical Letter on Drugs and Therapeutics • Feb 19, 2001  (Issue 1098)
of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Mathew Maurer, M.D ...
Palivizumab (Synagis - MedImmune), an injectable monoclonal antibody, has been marketed in the USA since 1999 for prevention of respiratory syncytial virus (RSV) disease in high-risk infants and children.
Med Lett Drugs Ther. 2001 Feb 19;43(1098):13-4 |  Show IntroductionHide Introduction

Formoterol (Foradil Aerolizer) For Asthma

   
The Medical Letter on Drugs and Therapeutics • May 14, 2001  (Issue 1104)
., University Hospital, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D ...
Formoterol fumarate inhalation powder Foradil Aerolizer, a long-acting beta2-adrenergic receptor agonist, has been approved by the FDA for maintenance treatment of asthma and prevention of exercise-induced bronchospasm. The drug has been available in Europe for many years.
Med Lett Drugs Ther. 2001 May 14;43(1104):39-40 |  Show IntroductionHide Introduction

Cefditoren (Spectracef) - A New Oral Cephalosporin

   
The Medical Letter on Drugs and Therapeutics • Jan 21, 2002  (Issue 1122)
. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Elizabeth Stephens, M.D., Oregon ...
Cefditoren pivoxil (Spectracef — TAP), a new oral third-generation cephalosporin, has been approved by the FDA for treatment of acute exacerbations of chronic bronchitis, pharyngitis, tonsillitis and uncomplicated skin and soft tissue infections in adults and children 12 or more years old. The drug has been used in Japan for 7 years.
Med Lett Drugs Ther. 2002 Jan 21;44(1122):5-6 |  Show IntroductionHide Introduction

Triptorelin Pamoate (Trelstar)

   
The Medical Letter on Drugs and Therapeutics • Jun 10, 2002  (Issue 1132)
, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University ...
Two controlled-release formulations of triptorelin (trip toe rel' in) pamoate, an agonist analog of human luteinizing hormone-releasing hormone (LHRH), are now available in the US for parenteral treatment of advanced prostate cancer. Trelstar Depot is given every 4 weeks and Trelstar LA every 12 weeks. Triptorelin has been available in some countries since 1986.
Med Lett Drugs Ther. 2002 Jun 10;44(1132):51-2 |  Show IntroductionHide Introduction

Tazarotene (Tazorac) for Acne

   
The Medical Letter on Drugs and Therapeutics • Jun 10, 2002  (Issue 1132)
., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS ...
Tazarotene (taz ar' oh teen, Tazorac - Allergan), an acetylinic retinoid marketed for treatment of psoriasis (Medical Letter 1997; 39:105), is also available as a 0.1% gel and cream for treatment of acne.
Med Lett Drugs Ther. 2002 Jun 10;44(1132):52-3 |  Show IntroductionHide Introduction

Gefitinib (Iressa) for advanced non-small cell lung cancer

   
The Medical Letter on Drugs and Therapeutics • Sep 02, 2002  (Issue 1138)
. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University of Manitoba ...
Patients with lung cancer may be asking their physicians about gefitinib (ge fi' tye nib; ZD1839; Iressa -- AstraZeneca), because it has been the subject of positive coverage in the media. An inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, this oral drug has not been approved by the FDA, but is in clinical trials in the US for treatment of non-small cell lung cancer (NSCLC) and some other solid tumors. Iressa was recently approved in Japan, and is available from the manufacturer on a "compassionate-use" basis in the US (800-236-9933).
Med Lett Drugs Ther. 2002 Sep 2;44(1138):77-8 |  Show IntroductionHide Introduction